Rami El Shafie, Professor for Precision Radiation Oncology at University Medical Center Göttingen, shared a post on LinkedIn about a paper he co-authored with colleagues published in Radiotherapy and Oncology:
“Happy to share the results of our secondary analysis of the CYBER-SPACE randomized phase II trial, published in Radiotherapy and Oncology by Annabella Schiele — and many thanks to the Heidelberg team for making this possible.
Objective:
To reassess established prognostic scores in patients receiving repeated SRS in combination with modern systemic therapies — a setting in which many traditional scores show limited validity.
Methods:
We analysed multiple prognostic tools (RPA, M-RPA, GPA, dsGPA, lung-mol GPA, BSBM, SIR, BMV) for their ability to predict:
Overall survival (OS)
WBRT indication (WBRTi) — defined as >10 brain metastases or leptomeningeal disease.
BMV was calculated at up to four distant brain failures.
Key Findings:
- 202 patients; median OS: 13.1 months
- BMV was the only score that reliably predicted both OS and WBRTi across all tumour entities
- Other established scores showed limited prognostic value in the context of modern SRS + systemic therapy, especially for WBRTi
- BMV remained prognostic through the 4th recurrence
- Two BMV cut-offs clearly separated prognostic groups for OS and WBRTi
Conclusion:
Brain Metastasis Velocity (BMV) is the only consistent and reliable prognostic marker for both survival and WBRT indication in patients undergoing repeated SRS under contemporary treatment standards.”
Title: Prognostic scores for patients with multiple brain metastases treated with repeated stereotactic radiosurgery − a secondary analysis of the CYBER-SPACE randomized phase 2 trial
Authors: Annabella Schiele, Denise Bernhardt, Thomas Welzel, Paul Thalmann, Laila König, Tanja Eichkorn, Anna Krämer, Kristin Lang, Adriane Lentz-Hommertgen, Fabian Weykamp, Farastuk Bozorgmehr, Michael Thomas, Anja Sander, Stefan Rieken, Jürgen Debus, Rami A. El Shafie
You can read the full article in Radiotherapy and Oncology.
